Apricus Biosciences (APRI) and Galena Biopharma (GALE) Head to Head Review
Galena Biopharma (NASDAQ: GALE) and Apricus Biosciences (NASDAQ:APRI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitabiliy, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.
This table compares Galena Biopharma and Apricus Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Galena Biopharma and Apricus Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Galena Biopharma||N/A||N/A||-$27.83 million||($0.94)||-0.61|
|Apricus Biosciences||$5.76 million||2.33||-$12.15 million||$0.31||3.39|
Apricus Biosciences has higher revenue and earnings than Galena Biopharma. Galena Biopharma is trading at a lower price-to-earnings ratio than Apricus Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
22.0% of Galena Biopharma shares are owned by institutional investors. Comparatively, 15.6% of Apricus Biosciences shares are owned by institutional investors. 0.8% of Galena Biopharma shares are owned by company insiders. Comparatively, 3.6% of Apricus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Galena Biopharma and Apricus Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Galena Biopharma currently has a consensus price target of $2.78, indicating a potential upside of 388.58%. Given Galena Biopharma’s higher probable upside, equities research analysts plainly believe Galena Biopharma is more favorable than Apricus Biosciences.
Volatility and Risk
Galena Biopharma has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Apricus Biosciences has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.
Apricus Biosciences beats Galena Biopharma on 7 of the 12 factors compared between the two stocks.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.
About Apricus Biosciences
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Receive News & Stock Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related stocks with our FREE daily email newsletter.